Publications by authors named "Sushmita D Lahiri"

Claim this Profile
T
The primary pharmacology of ceftazidime/avibactam: resistance in vitro.
Wright W Nichols, Sushmita D Lahiri, Patricia A Bradford, Gregory G Stone

J Antimicrob Chemother· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The primary pharmacology of ceftazidime/avibactam: in vitro translational biology.
Wright W Nichols, Patricia A Bradford, Sushmita D Lahiri, Gregory G Stone

J Antimicrob Chemother· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
Thomas F Durand-Réville, Janelle Comita-Prevoir, Jing Zhang, Xiaoyun Wu, Tricia L May-Dracka, Sushmita D Lahiri

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Narrow-Spectrum Antibacterial Agents-Benefits and Challenges.
Richard A Alm, Sushmita D Lahiri

Antibiotics (Basel)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
Renu Singh, Mashal Almutairi, Richard A Alm, Sushmita D Lahiri, Maryann San Martin

J Antimicrob Chemother· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs.
Sushmita D Lahiri, Richard A Alm

J Antimicrob Chemother· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.
Sushmita D Lahiri, Patricia A Bradford, Wright W Nichols, Richard A Alm

J Antimicrob Chemother· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-center and multi-method evaluation of in vitro activities of ceftaroline against S. aureus.
Laura M Koeth, Petra Apfalter, Karsten Becker, Giovanni Gesu, Luis Martínez-Martínez, Sushmita D Lahiri

Diagn Microbiol Infect Dis· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation Mapping.
David C McKinney, Charles J Eyermann, Rong-Fang Gu, Jun Hu, Steven L Kazmirski, Sushmita D Lahiri

ACS Infect Dis· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.
Sushmita D Lahiri, Richard A Alm

Antimicrob Agents Chemother· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.
Sushmita D Lahiri, Grant K Walkup, James D Whiteaker, Tiffany Palmer, Kathy McCormack

J Antimicrob Chemother· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline.
Sushmita D Lahiri, Richard A Alm

J Antimicrob Chemother· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.
Douglas J Biedenbach, Richard A Alm, Sushmita D Lahiri, Edina Reiszner, Daryl J Hoban

Antimicrob Agents Chemother· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.
Douglas J Biedenbach, Daryl J Hoban, Edina Reiszner, Sushmita D Lahiri, Richard A Alm

Antimicrob Agents Chemother· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.
Sushmita D Lahiri, Robert E McLaughlin, James D Whiteaker, Jane E Ambler, Richard A Alm

J Antimicrob Chemother· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus.
Sushmita D Lahiri, Amy Kutschke, Kathy McCormack, Richard A Alm

Antimicrob Agents Chemother· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftaroline Activity against mecC-Containing Staphylococcus aureus.
Sushmita D Lahiri, Richard A Alm

J Clin Microbiol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Gregory S Basarab, Gunther H Kern, John McNulty, John P Mueller, Kenneth Lawrence, Sushmita D Lahiri

Sci Rep· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel broad-spectrum inhibitors of bacterial methionine aminopeptidase.
Jonathan A Rose, Sushmita D Lahiri, David C McKinney, Rob Albert, Marshall L Morningstar

Bioorg Med Chem Lett· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Gregory S Basarab, Gunther H Kern, John McNulty, John P Mueller, Kenneth Lawrence, Sushmita D Lahiri

Sci Rep· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
Richard A Alm, Michele R Johnstone, Sushmita D Lahiri

J Antimicrob Chemother· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.
Richard A Alm, Sushmita D Lahiri, Amy Kutschke, Linda G Otterson, Robert E McLaughlin

Antimicrob Agents Chemother· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48.
Sushmita D Lahiri, Stefano Mangani, Haris Jahić, Manuela Benvenuti, Thomas F Durand-Reville

ACS Chem Biol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
Ning Gao, Sarah M McLeod, Laurel Hajec, Nelson B Olivier, Sushmita D Lahiri

Protein Expr Purif· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase.
David E Ehmann, Sushmita D Lahiri

Curr Opin Pharmacol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis